Stay updated with breaking news from Pelvic Lymph Node Dissection. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biochemical recurrence (BCR) of prostate cancer is a condition that occurs in men who have previously been cured of prostate cancer. In BCR, prostate-specific antigen (PSA) is elevated above normal.
Flotufolastat fluorine-18 (Posluma), a new PSMA-targeted PET radiopharmaceutical, has been approved in the US for use in prostate cancer.
Investigators say bladder-preserving treatment should be offered to all patients, not just poor surgical candidates.
No benefit was found in low-risk patients who underwent pelvic lymph node dissection (PLND).
Biochemical Recurrence of Prostate Cancer About The prostate is a walnut-sized gland that is a part of the male reproductive system. It secretes a fluid that nourishes and protects the sperms, which are the male reproductive cells. Cancer of the prostate is a major cause of concern in aging men. Prostate cancer usually resolves after primary therapy in the majority of men. However, in some men, a condition called biochemical recurrence (BCR) occurs, also known as biochemical relapse or PSA failure. In this condition, the prostate-specific antigen (PSA), a protein produced by the normal ...